Life Sciences

  • February 13, 2026

    FDA Removes Boxed Warnings From HRT Products

    Six menopause hormone therapies will no longer have warnings on their label about heart disease, breast cancer and dementia, after the U.S. Food and Drug Administration said it removed them so that women can make decisions "free from exaggeration or fear."

  • February 13, 2026

    How Attorneys Are Handling A Patent Review 'Sea Change'

    Major changes to the America Invents Act patent review system over the past year have put limits on challenges, requiring patent challengers and owners to rethink their strategies. Here's how attorneys on both sides are calibrating their arguments to have the best chance of success in the new landscape.

  • February 13, 2026

    J&J Hit With $250K Verdict In 2nd Philly Talc Trial

    A Philadelphia jury hit Johnson & Johnson with a $250,000 verdict on Friday, finding the company liable in the case of a woman whose family claimed that using the company's once-famous talcum powder contributed to her fatal ovarian cancer.

  • February 13, 2026

    CareDx Seeks High Court Review Of $45M False Ad Case

    Transplant diagnostics company CareDx has asked the U.S. Supreme Court to review a Third Circuit decision that erased a nearly $45 million jury award against rival Natera in a false advertising case, arguing the appeals court is the only one that forbids juries from inferring consumer deception when determining damages.

  • February 13, 2026

    Prenatal Testing Co. Missed Fatal Condition, Couple Say

    A Massachusetts couple say Natera Inc. misreported the results of tests for a genetic marker linked to a fatal kidney condition, leading to the conception of a child who died an hour after birth.

  • February 12, 2026

    FTC's PBM Case Paused For More Deal Talks

    Federal Trade Commission staffers are discussing potential settlements with OptumRx and Caremark that could end the agency's case accusing the pharmacy benefit managers of inflating insulin prices, following a recent deal with Express Scripts.

  • February 12, 2026

    Ex-Pharma Exec Fights AGs' Quick Win Bid In Antitrust Case

    A former pharmaceutical marketing executive urged a Connecticut federal court to reject summary judgment sought against him by state attorneys general pursuing wider price-fixing litigation against most of the generic drug industry, arguing key cooperating witnesses' questionable credibility makes a trial necessary.

  • February 12, 2026

    Astellas Gets $120M From Zydus In Bladder Drug Deal

    Generic-drug maker Zydus Pharmaceuticals has inked a $120 million deal to end a lawsuit accusing it of infringing Astellas Pharma Inc. patents covering bladder drug Myrbetriq, just two days after Lupin Pharmaceuticals made a similar deal.

  • February 12, 2026

    Goodwin Expands Healthcare Team With Ex-Reed Smith Atty

    A healthcare attorney specializing in guiding clients through regulatory and transactional matters has moved her practice to Goodwin Procter LLP's Philadelphia office after more than 11 years with Reed Smith LLP.

  • February 12, 2026

    Regeneron, Samsung Bioepis Settle Eye Med Patent Claims

    Regeneron Pharmaceuticals Inc. and Samsung Bioepis Co. Ltd. have told a West Virginia federal court they reached an agreement to end patent infringement claims brought by Regeneron over a biosimilar of its eye medication Eylea.

  • February 12, 2026

    McKesson Freed From Opioid Death Suit By Ga. Panel

    The Georgia Court of Appeals said Thursday that drug distributor McKesson should have been freed from a suit attempting to hold it liable for a man's opioid overdose death, saying that a trial court applied the wrong statute of limitations to what was, at its core, a personal injury claim.

  • February 11, 2026

    AbbVie Sues Medicaid, HHS Over Botox Fair Price Controls

    AbbVie Inc. on Wednesday asked a D.C. federal court to block the Centers for Medicare and Medicaid Services from controlling the price of Botox under the Inflation Reduction Act, arguing the cosmetic drug and migraine treatment should be excluded from the controls because it's a "plasma-derived" product.

  • February 11, 2026

    Pfizer, SEC Reach $29M Deal In Insider Trading Fund Dispute

    Pfizer and the U.S. Securities and Exchange Commission have jointly asked a New York federal judge to allow $29 million out of the roughly $75.2 million distribution leftover from a $602 million insider trading deal to be paid out to a Pfizer subsidiary.

  • February 11, 2026

    Luxottica Franchisee Gets Another Shot At Antitrust Claims

    An Ohio federal judge partially reversed course Wednesday after previously permanently tossing a Luxottica franchisee's antitrust claims, concluding that an attempt to amend them wouldn't be futile because it might be possible to show that allegedly suppressed insurance reimbursement rates were an ongoing violation that resets the statute of limitations.

  • February 11, 2026

    Biogen Beats Pharmacies' MS Drug Monopoly Suit, For Now

    An Illinois federal judge on Wednesday tossed out Walgreens and Kroger's lawsuit accusing Biogen Inc. of illegally stifling competition for its multiple sclerosis drug Tecfidera, but said the standing issues primarily dooming their complaint can likely be cured if they amend their pleading.

  • February 11, 2026

    NY Judge Rejects Bid To Stop SD Action Against Abortion Ads

    A New York federal judge said Wednesday that she can't block South Dakota officials from pursuing state legal action against an abortion rights group that launched an advertising campaign in South Dakota, saying she doesn't have jurisdiction to halt the proceedings.

  • February 11, 2026

    Supreme Court Sets April Argument For 'Skinny Label' Case

    The U.S. Supreme Court has set an April 29 date for oral arguments in Hikma Pharmaceutical Inc.'s appeal of a decision that revived a patent case over its "skinny label" on a generic heart drug.

  • February 11, 2026

    7th Circ. Mulls Expiration Date Of Teva, Eli Lilly Patent Deal

    Seventh Circuit judges Wednesday pressed counsel for Teva Pharmaceuticals USA Inc. to address how long a settlement under which Eli Lilly & Co. agreed not to block the approval and marketing of Teva's generic version of its osteoporosis drug Forteo could reasonably remain in effect, given Teva's drug wasn't ready for market until years after the underlying patent dispute.

  • February 11, 2026

    Shkreli Can't Add Wu-Tang Members To Fight With Crypto Co.

    "Pharma Bro" Martin Shkreli can't drag two members of the Wu-Tang Clan hip-hop group into a suit brought by a crypto firm that claims Shkreli improperly retained copies of an album that it bought the rights to, a New York federal judge ruled on Wednesday.

  • February 11, 2026

    Beasley Allen Wants Talc DQ Paused Pending High Court Appeal

    Hundreds of women who claim their ovarian cancer was caused by Johnson & Johnson's talcum powder risk appearing in an upcoming trial without their preferred counsel from the Beasley Allen Law Firm, unless a New Jersey state court stays an order disqualifying the firm, it said.

  • February 11, 2026

    Trans Health And Pediatric Groups Challenge FTC Subpoenas

    A major transgender medical group and a pediatric healthcare organization are seeking to end what they call "unlawful" consumer protection investigations from the Federal Trade Commission that want information pertaining to the medical groups' claims made in their marketing and advertising for gender-affirming care for minors. 

  • February 10, 2026

    Judge Limits Insurers' Exposure in Opioid Coverage Fight

    Insurers garnered several wins Tuesday in a dispute over coverage for thousands of opioid suits against bankrupt pharmaceutical company Endo International, with a Pennsylvania federal court ruling favorably for the carriers on the interpretation of claims-made provisions and the meaning of "damages for bodily injury."

  • February 10, 2026

    GSK, Teva Settle 'Skinny Label' Heart Medication Suit

    GlaxoSmithKline and Teva told a Delaware federal judge that they've settled GSK's decade-long "skinny label" patent fight over heart failure medication and asked the court to end the case.

  • February 10, 2026

    Jury Asked To 'Send A Message' To J&J As Talc Trial Wraps

    Counsel for a woman who died of ovarian cancer asked a Philadelphia jury to "send a message" with its verdict at the closing of the court's second talc mass tort trial against Johnson & Johnson, suggesting they should consider the company's multibillion-dollar net worth when coming up with a punitive damages award.

  • February 10, 2026

    Lutnick Rules Out Creating Value-Based Fees For Patents

    Commerce Secretary Howard Lutnick told a Senate panel Tuesday that the government is not planning to establish new fees for U.S. patents based on their value, saying the idea he was reportedly considering "is not going anywhere."

Expert Analysis

  • Series

    Being A Professional Wrestler Makes Me A Better Lawyer

    Author Photo

    Pursuing my childhood dream of being a professional wrestler has taught me important legal career lessons about communication, adaptability, oral advocacy and professionalism, says Christopher Freiberg at Midwest Disability.

  • Patent Claim Lessons From Fed. Circ.'s Teva Decision

    Author Photo

    The Federal Circuit's recent decision in Janssen v. Teva is an important precedent for parties drafting patent claims or litigating obviousness where the prior art has potentially overlapping ranges for a claimed element, and may be particularly instructive to patent applicants in the pharmaceutical field, say attorneys at Cooley.

  • Series

    Law School's Missed Lessons: Adapting To The Age Of AI

    Author Photo

    Though law school may not have specifically taught us how to use generative artificial intelligence to help with our daily legal tasks, it did provide us the mental building blocks necessary for adapting to this new technology — and the judgment to discern what shouldn’t be automated, says Pamela Dorian at Cozen O'Connor.

  • Ch. 11 Ruling Voiding $2M Litigation Funding Sends A Warning

    Author Photo

    A recent Texas bankruptcy court decision that a postconfirmation litigation trust has no obligations to repay a completely drawn down $2 million litigation funding agreement serves as a warning for estate administrators and funders to properly disclose the intended financing, say attorneys at Kleinberg Kaplan.

  • DOJ's Novel Cybersecurity FCA Case Is A Warning To Medtech

    Author Photo

    The U.S. Department of Justice's recent False Claims Act settlement with Illumina over alleged cybersecurity deficiencies suggests that enforcement agencies and whistleblowers are focusing attention toward cybersecurity in life sciences and medical tech, but also reveals key unanswered questions about the legal viability of such allegations, say attorneys at Morgan Lewis.

  • Future-Proof Patent Law By Starting Talent Pipelines Early

    Author Photo

    Law firms struggling with a narrow talent pipeline in the intellectual property space should consider beginning their recruitment strategies for potential candidates as early as high school, and raise awareness for career opportunities that do not require a law degree, says Christine Hollis at Marshall Gerstein.

  • Demystifying The Civil Procedure Rules Amendment Process

    Author Photo

    Every year, an advisory committee receives dozens of proposals to amend the Federal Rules of Civil Procedure, most of which are never adopted — but a few pointers can help maximize the likelihood that an amendment will be adopted, says Josh Gardner at DLA Piper.

  • How USPTO Examiner Memo Informs Software Patent Drafting

    Author Photo

    A memorandum recently released by the U.S. Patent and Trademark Office provides useful clues as to how the USPTO and examining corps will evaluate claims in software-implemented inventions for subject matter eligibility going forward, says Michael Lew at Squire Patton.

  • How 2nd Circ. Cannabis Ruling Upends NY Licensing

    Author Photo

    A recent Second Circuit decision in Variscite NY Four v. New York, holding that New York's extra-priority cannabis licensing preference for applicants with in-state marijuana convictions violates the dormant commerce clause, underscores that state-legal cannabis markets remain subject to the same constitutional constraints as other economic markets, say attorneys at Harris Beach.

  • Parenting Skills That Can Help Lawyers Thrive Professionally

    Author Photo

    As kids head back to school, the time is ripe for lawyers who are parents to consider how they can incorporate their parenting skills to build a deep, meaningful and sustainable legal practice, say attorneys at Alston & Bird.

  • Enablement Standard Insights From Fed. Circ. Agilent Ruling

    Author Photo

    The Federal Circuit's recent enablement standard decision in Agilent v. Synthego underscores three critical takeaways for patent practitioners, including reaffirmation that the enablement inquiry under Section 102 of the Patent Act is distinct from the inquiry under Section 112, say attorneys at MoFo.

  • Series

    Teaching Trial Advocacy Makes Us Better Lawyers

    Author Photo

    Teaching trial advocacy skills to other lawyers makes us better litigators because it makes us question our default methods, connect to young attorneys with new perspectives and focus on the needs of the real people at the heart of every trial, say Reuben Guttman, Veronica Finkelstein and Joleen Youngers.

  • The Crucial Question Left Unanswered In EpicentRx Decision

    Author Photo

    The California Supreme Court recently issued its long-awaited decision in EpicentRx Inc. v. Superior Court, resolving a dispute regarding the enforceability of forum selection clauses, but the question remains whether private companies can trust that courts will continue to consistently enforce forum selection clauses in corporate charters, says John Yow at Yow PC.

  • Federal AI Action Plan Marks A Shift For Health And Bio Fields

    Author Photo

    The Trump administration's recent artificial intelligence action plan significantly expands federal commitments across biomedical agencies, defining a pivotal moment for attorneys and others involved in research collaborations, managing regulatory compliance and AI-related intellectual property, says Mehrin Masud-Elias at Arnold & Porter.

  • Preparing For DEA Rescheduling Of 2 Research Chemicals

    Author Photo

    A recent decision to allow the U.S. Drug Enforcement Administration to reclassify two research psychedelics in Schedule I under the Controlled Substances Act may pose significant barriers to scientific study, including stringent registration requirements, heightened security protocols and burdensome reporting obligations, say Kimberly Chew at Husch Blackwell and Jackie von Salm at Psilera.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.